NYSEArca - Nasdaq Real Time Price USD
iShares MSCI Brazil ETF (EWZ)
32.46 -0.68 (-2.05%)
At close: October 30 at 4:00:00 p.m. EDT
32.48 +0.02 (+0.06%)
After hours: October 30 at 7:55:48 p.m. EDT
Chart Range Bar
Loading chart for EWZ
- Previous Close
33.14 - Open
32.47 - Bid 32.38 x 1540000
- Ask 32.61 x 1860000
- Day's Range
32.21 - 32.88 - 52 Week Range
30.72 - 43.90 - Volume
54,778,673 - Avg. Volume
41,096,007 - Net Assets 8.64B
- NAV 32.46
- PE Ratio (TTM) 9.38
- Yield 3.94%
- YTD Daily Total Return 3.15%
- Beta (5Y Monthly) 0.83
- Expense Ratio (net) 0.59%
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization-weighted index designed to measure the performance of the large- and mid- capitalization segments of the equity market in Brazil. The fund is non-diversified.
iShares
Fund Family
Focused Region
Fund Category
8.64B
Net Assets
2000-07-10
Inception Date
Performance Overview
View MoreTrailing returns as of 2026-10-31. Category is Focused Region.
Recent News
View More
Research Reports
View MoreBiogen Earnings: Apellis Products Boost Growth Ahead of Key Lupus Readout
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Raising rating to BUY
Biogen Inc. is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for SMA and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Tencent Leverages Unrivaled Network Effects to Fuel Growth on Multiple Fronts
Tencent is the world’s largest game publisher, with top‑grossing mobile hits like Honor of Kings and Peacekeeper Elite and a steady pipeline of new titles. It also operates WeChat—China’s super‑app with roughly 1.3 billion users—embedded in daily life for messaging, short video, mini programs, payments, and shopping. Beyond its own platforms, Tencent is a prolific strategic investor, holding stakes in leading internet companies such as PDD, Kuaishou, and Xiaohongshu.